Zhao X, Qi X, Liu D, Che X, Wu G
Int J Nanomedicine. 2024; 19:13461-13483.
PMID: 39713223
PMC: 11662911.
DOI: 10.2147/IJN.S498729.
Wei Y, Li R, Wang Y, Fu J, Liu J, Ma X
Int J Nanomedicine. 2024; 19:10129-10144.
PMID: 39381025
PMC: 11460276.
DOI: 10.2147/IJN.S466315.
Joyce P, Allen C, Alonso M, Ashford M, Bradbury M, Germain M
Nat Nanotechnol. 2024; 19(11):1597-1611.
PMID: 39242807
DOI: 10.1038/s41565-024-01754-7.
Sun Y, Lu Y, Li X, He Y, Yong T, Keng C
Cell Death Dis. 2024; 15(8):632.
PMID: 39198434
PMC: 11358381.
DOI: 10.1038/s41419-024-07008-7.
Dai T, Wang Q, Zhu L, Luo Q, Yang J, Meng X
Int J Nanomedicine. 2024; 19:8519-8540.
PMID: 39185349
PMC: 11345023.
DOI: 10.2147/IJN.S459960.
An artificial signaling pathway primitive-based intelligent biomimetic nanoenzymes carrier platform for precise treatment of Her2 (+) tumors.
Sun Y, Zhang W, Lu Y, He Y, Yahaya B, Liu Y
Mater Today Bio. 2024; 26:101105.
PMID: 38933416
PMC: 11201151.
DOI: 10.1016/j.mtbio.2024.101105.
Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications.
Cao Z, Liu C, Wen J, Lu Y
Adv Mater. 2024; 36(41):e2403116.
PMID: 38819929
PMC: 11571700.
DOI: 10.1002/adma.202403116.
Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.
Avgoustakis K, Angelopoulou A
Pharmaceutics. 2024; 16(2).
PMID: 38399240
PMC: 10892652.
DOI: 10.3390/pharmaceutics16020179.
Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities.
Wang J, Zhao Y, Nie G
Med Rev (2021). 2024; 3(4):321-342.
PMID: 38235406
PMC: 10790212.
DOI: 10.1515/mr-2023-0028.
The Transformative Potential of Lipid Nanoparticle-Protein Corona for Next-Generation Vaccines and Therapeutics.
Amici A, Pozzi D, Marchini C, Caracciolo G
Mol Pharm. 2023; 20(11):5247-5253.
PMID: 37782816
PMC: 10630956.
DOI: 10.1021/acs.molpharmaceut.3c00479.
The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential.
Slama Y, Ah-Pine F, Khettab M, Arcambal A, Begue M, Dutheil F
Int J Mol Sci. 2023; 24(17).
PMID: 37686315
PMC: 10488262.
DOI: 10.3390/ijms241713511.
Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.
Matos A, Peres C, Carreira B, Moura L, Acurcio R, Vogel T
Adv Sci (Weinh). 2023; 10(25):e2300299.
PMID: 37434063
PMC: 10477894.
DOI: 10.1002/advs.202300299.
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.
Anand U, Dey A, Chandel A, Sanyal R, Mishra A, Pandey D
Genes Dis. 2023; 10(4):1367-1401.
PMID: 37397557
PMC: 10310991.
DOI: 10.1016/j.gendis.2022.02.007.
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.
Subhan M, Parveen F, Filipczak N, Yalamarty S, Torchilin V
J Pers Med. 2023; 13(3).
PMID: 36983571
PMC: 10051487.
DOI: 10.3390/jpm13030389.
CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma.
Liu J, Mu W, Gao T, Fang Y, Zhang N, Liu Y
Pharmaceutics. 2023; 15(2).
PMID: 36839748
PMC: 9962034.
DOI: 10.3390/pharmaceutics15020426.
Albumin-based nanoparticles: small, uniform and reproducible.
Thalhammer-Thurner G, Debbage P
Nanoscale Adv. 2023; 5(2):503-512.
PMID: 36756267
PMC: 9846714.
DOI: 10.1039/d2na00413e.
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.
Dilliard S, Siegwart D
Nat Rev Mater. 2023; 8(4):282-300.
PMID: 36691401
PMC: 9850348.
DOI: 10.1038/s41578-022-00529-7.
Stability, spectroscopic, electrochemistry and QTAIM analysis of Cu-ZnO clusters for glucose sensing application: A study on theoretical and experimental insights.
Gassoumi B, Dlala N, Echabaane M, Karayel A, Ozkinali S, Castro M
Heliyon. 2022; 8(12):e12387.
PMID: 36582723
PMC: 9793285.
DOI: 10.1016/j.heliyon.2022.e12387.
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?.
Timon-David E, Perez C, Rodallec A
Pharmaceutics. 2022; 14(11).
PMID: 36365144
PMC: 9697974.
DOI: 10.3390/pharmaceutics14112326.
Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience.
Amin M, Seynhaeve A, Sharifi M, Falahati M, Ten Hagen T
Pharmaceutics. 2022; 14(10).
PMID: 36297598
PMC: 9607095.
DOI: 10.3390/pharmaceutics14102165.